The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped ...

The maker of Ozempic and Wegovy obesity drugs said some of the prices could come down, as President Trump called for ...

The outgoing chief executive of Novo Nordisk has revealed plans to ramp-up cost cutting 'efficiencies' across the business, ...

Muscle and strength loss in human aging, also known as sarcopenia, can result in trouble with balance and walking, according ...

Novo NordiskNVO stock slumped Wednesday after the drugmaker said it expects continued competition this year from "unsafe and ...

Levi & Korsinsky is representing the shareholder plaintiff in a suit claiming the Ozempic and Wegovy manufacturer withheld ...

Danish pharmaceutical giant Novo Nordisk posted a sharp rise in second-quarter net profit Wednesday, but rising competition ...

Novo Nordisk A/S (NYSE:NVO), the Danish pharmaceutical giant renowned for its weight-loss drug Wegovy and diabetes treatment ...

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to ...

The Danish firm blamed the move to slash its guidance on intense competition from rivals and copycat drugs in the US.

As of 2024, Brazil's Semaglutide market was estimated at $581 million. The global market size for the GLP-1 (glucagon-like ...

Despite this, one in five young adults who meet the criteria for the drugs are uninsured and one-third denied having a routine place for healthcare.